North American Internal Neurostimulation Market

The North American internal neurostimulation devices market is mainly driven by the rapidly aging population and associated diseases like Alzheimer’s, epilepsy, spinal cord injury, and Parkinson’s disease. It is expected to grow at a CAGR of 11.8% in the next five years. This is primarily due to the technical advances and patient-friendly techniques such as minimally invasive and non-invasive. The North American internal neurostimulation market was $2548.27 million in 2013, and is expected to reach $4242.09 million by 2018, at a CAGR of 10.7%.The internal neuromodulation market contributed the largest share of 87% to the overall neurostimulation market.

The report ‘North American Internal Neurostimulation Devices Market forecast, 2012-2018’ analyzes the internal neurostimulation market segmented by modalities including spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES). The report includes applications, such as chronic pain, failed back surgery syndrome, refractory angina pectoris, peripheral neuropathy, Alzheimer’s, Dystonia, Tourette’s syndrome, Parkinson’s, epilepsy, fecal incontinence, urine incontinence, and gastroparesis.

These segments are expected to experience a positive growth until 2018, with an increased awareness for procedures and sophisticated diagnostic techniques. With a market value of $2.3 and $0.6 billion, the spinal cord stimulation (SCS) and deep brain stimulation (DBS) segments have been contributing 51% and 14%, in terms of value, towards total internal neurostimulation device market. Both the markets have been witnessing high growth because of increase in patient pool and procedure numbers of spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES).

Procedure volume growth is significantly higher in the U.S and Mexico because of fast disease progression, improving healthcare infrastructure, economic growth, broadening insurance coverage, expanding private healthcare sector, and increasing awareness amongst people.

According to the International Neurostimulation Society, about 40 million patients worldwide suffer from epilepsy and 1.5 million from Parkinson’s, in the U.S. alone. A wide pool of patients suffering from other conditions, such as depression, stroke, anxiety disorders, lower back pain, urinary incontinence, and tremor are also an influential factor in triggering the market growth. Treatment for tinnitus represents one of the emerging applications in this market. According to the American Tinnitus Association, about 50 million people in the U.S. suffer from this disease.

The prevalence of Alzheimer’s in Europe and North America is around 6.4-5.4% in adults, whereas in Asia, it is around 4%. The reason for prevalence in Asia is a growth in the aging population, whereas in North America and Europe it’s because of population suffering from diabetes and obesity. The incidence of Alzheimer’s was 411,000 in 2000. This increased to 454,000 in 2010. It is expected to reach 615,000 by 2030 and 959,000 by 2050. Such high incidences rate in neurological disorders will positively affect the market for neuromodulation.

The report also provides an extensive competitive landscaping of companies operating in North American internal neurostimulation market. The key players dominating the internal neurostimulation market include Medtronic, Boston Scientific, St. Jude Medical, Cyberonics, Enteromedics, Neurotech, Cerebomed, Microtransponder, and BioControl Medical.

Segment and country-specific company shares, news & deals, mergers and acquisitions, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed.

Customization Options

Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:

• Product Analysis
  • Usage pattern (in-depth trend analysis) of products (segment wise)
  • Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment level
  • End-user adoption rate analysis of the products (segment wise and country wise)
  • Comprehensive coverage of product approvals, pipeline products, and product recalls

• Epidemiology Data
  • Country-specific prevalence of Alzheimer’s, Parkinson’s, epilepsy, and stroke
  • Country-specific incidence of Alzheimer’s, Parkinson’s, epilepsy, and stroke
  • Country-specific mortality rate of stroke and epilepsy
  • Country-specific patient pool of Alzheimer’s, Parkinson’s, epilepsy, and stroke
  • Disease progression (pattern analysis)

• Procedure Volume Data
  • Country-wise number of surgeries for epilepsy, heart failure, Alzheimer’s, and Parkinson’s

• Surgeons/Physicians Perception Analysis
  • Fast turn-around analysis of surgeons’ response to market events and trends
  • Pattern analysis of usage of spinal cord stimulation (SCS) and deep brain stimulation (DBS) by physicians
  • Surgeons’ opinion about products from different companies
  • Surgeons’ qualitative inputs on epidemiology data

• Brand/Product Perception Matrix
  • Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
  • Analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)

• Pricing Trends
  • Cost analysis of North American internal neurostimulation devices
  • Procedural investments in North American internal neurostimulation

• Competitive Intelligence
  • The company share analysis of the top players in the North American internal neurostimulation market
  • The crucial developments and strategies of companies inculcated in their portfolio  of internal neurostimulation

1 Introduction

1.1 Introduce the Market

1.2 Objective of the study

1.3 Market Definition and Scope of the study

1.3.1 Market Definition

1.3.2 Areas covered

1.3.3 Markets Covered

1.4 Stakeholders

1.5 Research Methodology

1.5.1 Secondary sources

1.5.2 Primary Sources

1.5.3 Market estimation methodology (Top-down, bottom-up, data triangulation.)

1.5.4 Macro indicators for the study

1.6 Assumptions

1.7 List of Acronyms

2 Market Overview

3 Internal Neurostimulation-North America, By SurgeryProcedures

3.1 Split By Geography

3.2 Internal Neurostimulation-North America-Direct Nerve Repair

3.2.1 Internal Neurostimulation-North America-Direct Nerve Repair, By Geographies

3.2.1.1 Internal Neurostimulation-U.S.-Direct Nerve Repair

3.2.1.2 Internal Neurostimulation-Canada-Direct Nerve Repair

3.2.1.3 Internal Neurostimulation-Mexico-Direct Nerve Repair

3.3 Internal Neurostimulation-Nerve Grafting-North America

3.4 Internal Neurostimulation-Stem cell therapy-North America

4 Internal Neurostimulation-North America, By Types

4.1 Split By Geography

4.2 Spinal cord stimulator-North America

4.2.1 Spinal cord stimulator-North America, By Applications

4.2.1.1 Spinal cord stimulator-Chronic Pain-North America

4.2.1.2 Spinal cord stimulator-Spinal Cord Injury-North America

4.2.1.3 Spinal cord stimulator-Ischemic heart disease-North America

4.2.1.4 Spinal cord stimulator-Others-North America

4.2.2 Spinal cord stimulator-North America, By Geographies

4.2.2.1 Spinal cord stimulator-U.S.

4.2.2.2 Spinal cord stimulator-Canada

4.2.2.3 Spinal cord stimulator-Mexico

4.3 Deep Brain Stimulator-North America

4.3.1 Deep Brain Stimulator-North America, By Applications

4.3.1.1 Deep Brain Stimulator-Parkinson’s Disease-North America

4.3.1.2 Deep Brain Stimulator-Other Applications-North America

4.3.1.3 Deep Brain Stimulator-Coma and Brain Death-North America

4.3.1.4 Deep Brain Stimulator-Depression-North America

4.3.2 Deep Brain Stimulator-North America, By Geographies

4.3.2.1 Deep Brain Stimulator-U.S.

4.3.2.2 Deep Brain Stimulator-Canada

4.3.2.3 Deep Brain Stimulator-Mexico

4.4 Sacral Nerve Stimulator-North America

4.4.1 Sacral Nerve Stimulator-North America, By Applications

4.4.1.1 Sacral Nerve Stimulator-Urine Incontinence-North America

4.4.1.2 Sacral Nerve Stimulator-Fecal Incontinence-North America

4.4.2 Sacral Nerve Stimulator-North America, By Geographies

4.4.2.1 Sacral Nerve Stimulator-U.S.

4.4.2.2 Sacral Nerve Stimulator-Canada

4.4.2.3 Sacral Nerve Stimulator-Mexico

4.5 Vagus Nerve Stimulator-North America

4.5.1 Vagus Nerve Stimulator-North America, By Applications

4.5.1.1 Vagus Nerve Stimulator-Epilepsy-North America

4.5.1.2 Vagus Nerve Stimulator-Other Applications-North America

4.5.2 Vagus Nerve Stimulator-North America, By Geographies

4.5.2.1 Vagus Nerve Stimulator-U.S.

4.5.2.2 Vagus Nerve Stimulator-Canada

4.5.2.3 Vagus Nerve Stimulator-Mexico

4.6 Gastric Electrical stimulator-North America

4.6.1 Gastric Electrical stimulator-North America, By Applications

4.6.1.1 Gastric Electrical stimulator-Gastroparesis-North America

4.6.1.2 Gastric Electrical stimulator-Others-North America

4.6.2 Gastric Electrical stimulator-North America, By Geographies

4.6.2.1 Gastric Electrical stimulator-U.S.

4.6.2.2 Gastric Electrical stimulator-Canada

4.6.2.3 Gastric Electrical stimulator-Mexico

5 Internal Neurostimulation-North America, By Geographies

5.1 Internal Neurostimulation-U.S.

5.1.1 Internal Neurostimulation-U.S., By SurgeryProcedures

5.1.1.1 Internal Neurostimulation-U.S.-Direct Nerve Repair

5.1.1.2 Internal Neurostimulation-U.S.-Nerve Grafting

5.1.1.3 Internal Neurostimulation-U.S.-Stem cell therapy

5.1.2 Internal Neurostimulation-U.S., By Companies

5.1.2.1 Internal Neurostimulation-U.S.-Medtronic, Inc.

5.1.2.2 Internal Neurostimulation-U.S.-St. Jude Medical, Inc.

5.1.2.3 Internal Neurostimulation-U.S.-Boston Scientific

5.1.2.4 Internal Neurostimulation-U.S.-Other Companies

5.1.2.5 Internal Neurostimulation-U.S.-Cyberonics

5.1.2.6 Internal Neurostimulation-U.S.-Biocontrol Medical

5.1.2.7 Internal Neurostimulation-U.S.-Johnson & Johnson

5.1.2.8 Internal Neurostimulation-U.S.-Greatbatch Inc

5.1.3 Internal Neurostimulation-U.S., By Types

5.1.3.1 Spinal cord stimulator-U.S.

5.1.3.2 Deep Brain Stimulator-U.S.

5.1.3.3 Sacral Nerve Stimulator-U.S.

5.1.3.4 Vagus Nerve Stimulator-U.S.

5.1.3.5 Gastric Electrical stimulator-U.S.

5.2 Internal Neurostimulation-Canada

5.2.1 Internal Neurostimulation-Canada, By Companies

5.2.1.1 Internal Neurostimulation-Canada-Medtronic, Inc.

5.2.1.2 Internal Neurostimulation-Canada-St. Jude Medical, Inc.

5.2.1.3 Internal Neurostimulation-Canada-Boston Scientific

5.2.1.4 Internal Neurostimulation-Canada-Cyberonics

5.2.1.5 Internal Neurostimulation-Canada-Other Companies

5.2.1.6 Internal Neurostimulation-Canada-Biocontrol Medical

5.2.1.7 Internal Neurostimulation-Canada-Johnson & Johnson

5.2.1.8 Internal Neurostimulation-Canada-Greatbatch Inc

5.2.2 Internal Neurostimulation-Canada, By SurgeryProcedures

5.2.2.1 Internal Neurostimulation-Canada-Direct Nerve Repair

5.2.2.2 Internal Neurostimulation-Canada-Nerve Grafting

5.2.2.3 Internal Neurostimulation-Canada-Stem cell therapy

5.2.3 Internal Neurostimulation-Canada, By Types

5.2.3.1 Spinal cord stimulator-Canada

5.2.3.2 Deep Brain Stimulator-Canada

5.2.3.3 Sacral Nerve Stimulator-Canada

5.2.3.4 Vagus Nerve Stimulator-Canada

5.2.3.5 Gastric Electrical stimulator-Canada

5.3 Internal Neurostimulation-Mexico

5.3.1 Internal Neurostimulation-Mexico, By Companies

5.3.1.1 Internal Neurostimulation-Mexico-Medtronic, Inc.

5.3.1.2 Internal Neurostimulation-Mexico-Other Companies

5.3.1.3 Internal Neurostimulation-Mexico-St. Jude Medical, Inc.

5.3.1.4 Internal Neurostimulation-Mexico-Boston Scientific

5.3.1.5 Internal Neurostimulation-Mexico-Cyberonics

5.3.1.6 Internal Neurostimulation-Mexico-Biocontrol Medical

5.3.1.7 Internal Neurostimulation-Mexico-Johnson & Johnson

5.3.1.8 Internal Neurostimulation-Mexico-Greatbatch Inc

5.3.2 Internal Neurostimulation-Mexico, By SurgeryProcedures

5.3.2.1 Internal Neurostimulation-Mexico-Direct Nerve Repair

5.3.2.2 Internal Neurostimulation-Mexico-Nerve Grafting

5.3.2.3 Internal Neurostimulation-Mexico-Stem cell therapy

5.3.3 Internal Neurostimulation-Mexico, By Types

5.3.3.1 Spinal cord stimulator-Mexico

5.3.3.2 Deep Brain Stimulator-Mexico

5.3.3.3 Sacral Nerve Stimulator-Mexico

5.3.3.4 Vagus Nerve Stimulator-Mexico

5.3.3.5 Gastric Electrical stimulator-Mexico

6 Internal Neurostimulation-North America, By Companies

6.1 Split By Geography

6.2 Internal Neurostimulation-North America-Medtronic, Inc.

6.2.1 Internal Neurostimulation-North America-Medtronic, Inc., By Geographies

6.2.1.1 Internal Neurostimulation-U.S.-Medtronic, Inc.

6.2.1.2 Internal Neurostimulation-Canada-Medtronic, Inc.

6.2.1.3 Internal Neurostimulation-Mexico-Medtronic, Inc.

6.3 Internal Neurostimulation-North America-St. Jude Medical, Inc.

6.3.1 Internal Neurostimulation-North America-St. Jude Medical, Inc., By Geographies

6.3.1.1 Internal Neurostimulation-U.S.-St. Jude Medical, Inc.

6.3.1.2 Internal Neurostimulation-Canada-St. Jude Medical, Inc.

6.3.1.3 Internal Neurostimulation-Mexico-St. Jude Medical, Inc.

6.4 Internal Neurostimulation-North America-Boston Scientific

6.4.1 Internal Neurostimulation-North America-Boston Scientific, By Geographies

6.4.1.1 Internal Neurostimulation-U.S.-Boston Scientific

6.4.1.2 Internal Neurostimulation-Canada-Boston Scientific

6.4.1.3 Internal Neurostimulation-Mexico-Boston Scientific

6.5 Internal Neurostimulation-North America-Other Companies

6.5.1 Internal Neurostimulation-North America-Other Companies, By Geographies

6.5.1.1 Internal Neurostimulation-U.S.-Other Companies

6.5.1.2 Internal Neurostimulation-Canada-Other Companies

6.5.1.3 Internal Neurostimulation-Mexico-Other Companies

6.6 Internal Neurostimulation-North America-Cyberonics

6.6.1 Internal Neurostimulation-North America-Cyberonics, By Geographies

6.6.1.1 Internal Neurostimulation-U.S.-Cyberonics

6.6.1.2 Internal Neurostimulation-Canada-Cyberonics

6.6.1.3 Internal Neurostimulation-Mexico-Cyberonics

6.7 Internal Neurostimulation-North America-Biocontrol Medical

6.7.1 Internal Neurostimulation-North America-Biocontrol Medical, By Geographies

6.7.1.1 Internal Neurostimulation-U.S.-Biocontrol Medical

6.7.1.2 Internal Neurostimulation-Canada-Biocontrol Medical

6.7.1.3 Internal Neurostimulation-Mexico-Biocontrol Medical

6.8 Internal Neurostimulation-North America-Johnson & Johnson

6.8.1 Internal Neurostimulation-North America-Johnson & Johnson, By Geographies

6.8.1.1 Internal Neurostimulation-U.S.-Johnson & Johnson

6.8.1.2 Internal Neurostimulation-Canada-Johnson & Johnson

6.8.1.3 Internal Neurostimulation-Mexico-Johnson & Johnson

6.9 Internal Neurostimulation-North America-Greatbatch Inc

6.9.1 Internal Neurostimulation-North America-Greatbatch Inc, By Geographies

6.9.1.1 Internal Neurostimulation-U.S.-Greatbatch Inc

6.9.1.2 Internal Neurostimulation-Canada-Greatbatch Inc

6.9.1.3 Internal Neurostimulation-Mexico-Greatbatch Inc

Please fill in the form below to receive a free copy of the Summary of this Report

* First Name :

* Last Name :

* Designation :

* Company :

* Email(Username) :

* Phone :

* Country :

-- Select Country -- India Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antigua Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia Herzegovina Botswana Brazil British Virgin Island Brunei Darussalam Bulgaria Burkina Faso Burundi Cote d'Ivoire Cambodia Cameroon Canada Cape Verde Cayman Isls Central African Republic Chad Chile China Colombia Comoros Congo Cook Island Costa Rica Croatia Cuba Cyprus Czech Republic Democratic People's Republic of Korea Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Faroe Islands Falkland Islands (Malvinas) Fiji Finl France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenl Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Holy See Honduras Hong Kong Special Administrative Hungary Iceland Indonesia Iran (Islamic Republic of Iran) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Special Administrative Region of China Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Micronesia Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherland Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Islands Northern Mariana Islands Norway Occupied Palestinian Territory Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Republic of Korea Republic of Moldova Romania Russian Federation Rwa Saint Helena Saint Kitts Nevis Saint Lucia Saint Pierre Miquelon Saint Vincent the Grenadines Samoa San Marino Sao Tome Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka Sudan Suriname Svalbard Jan Mayen Islands Swazil Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Thailand The former Yugoslav Republic of Macedonia Timor-Leste Togo Tokelau Tonga Trinidad Tobago Tunisia Turkey Turkmenistan Turks Caicos Isls Tuvalu Uga Ukraine United Arab Emirates United Kingdom United Republic of Tanzania United States United States Virgin Isls Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Wallis Futuna Isls Western Sahara Yemen Yugoslavia Zambia Zimbabwe

Comments :

Reports Interested in :North American Internal Neurostimulation Market

* Enter the text from the image to the text box :